# Pneumonia

[2018台灣肺炎指引](https://pneumonia.idtaiwanguideline.org/) 

## Microbiology of Pneumonia

| Clinical Setting                                             | 原因                                                         |
| ------------------------------------------------------------ | ------------------------------------------------------------ |
| Community- acquired (CAP)  ([NEJM 2014;371:1619](https://www.nejm.org/doi/10.1056/NEJMra1312885) &  373:415; Lancet 2015;386:1097) | No pathogen identified in 50–60%, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in <5% <br />Viruses: influenza, RSV, hMPV, rhinovirus (unknown significance), parainfluenza virus, coronavirus  <br />S. pneumoniae (most common bacterial cause)  <br />S. aureus (esp. postinfluenza) Mycoplasma, Chlamydia (特別在 young & healthy)  <br />H. influenzae, M. catarrhalis (特別在 COPD) <br />Legionella (特別在 elderly, smokers, ↓ immunity, TNF inhibitors) Klebsiella & other GNR (特別在 alcoholics & aspiration) |
| Hospital-acquired or ventilator-assoc. (HAP/VAP)             | S. aureus, Pseudo., Klebsiella, E. coli, Enterobacter, Acinetobacter, Stenotrophomonas. IV abx w/in 90 d RF for MDR.  <br />Viral~ 20% cases (Chest 2017; 154:1) |
| Immunosuppressed                                             | Above + PCP, fungi, Nocardia, non-TB mycobacteria (NTM), CMV |
| Aspiration [(NEJM  2019;380:651)](https://www.nejm.org/doi/full/10.1056/nejmra1714562) | Chemical pneumonitis due to aspiration of gastric contents <br />Bacterial pneumonia ≥24–72 h after aspiration  event outPt: oral flora (strep, S. aureus,  anaerobes) inPt or chronically ill: GNR (Pseudomonas) and S. aureus |

![img](https://i.imgur.com/NmWZ3Ix.jpg)

## Clinical manifestations

* Presenting features are variable and depend upon several host factors (esp. age)
* Classically: fever, cough w/ purulent sputum, consolidation on CXR
* Atypical pathogens (Legionella, Mycoplasma, Chlamydia, virus): historically classified as “atypical” b/c they failed to grow on routine cx. Presentation varies from insidious to acute; imaging features vary from interstitial infiltrates to tree-in-bud opacities, to dense consolid.
* Clinical and imaging features do NOT distinguish “typical” from “atypical”
* Aspiration pneumonitis/PNA: can be infectious or non-infectious; may p/w acute inflammatory syndrome (fever, ↑ WBC, etc.) or insidious course
* HAP/VAP: develops w/in 48 h after admission or mechanical ventilation, respectively

## Diagnostic studies

* Sputum Gram stain/Cx: reliable if high quality (ie, sputum not spit; <10 squamous cells/lpf) & if PNA should be purulent (>25 PMNs/lpf). Yield ↓ >10 h after abx (CID 2014;58:1782).
* Blood cultures (before antibiotics!): ⊕ in ~10% of inPts, depending on pathogen
* Procalcitonin: ↑ in acute bacterial (not viral) PNA. Consider stopping abx if levels <0.25 ng/ml (<0.5 ng/ml in ICU Pts) or ↓ ≥80% from peak. ↓ abx exposure by 2–3 d (Lancet ID 2016;16:819 & 2018;18:95). Not validated in immunocompromised hosts. Levels harder to interpret in CKD. False ⊕ in cardiac arrest, shock, surgery.
* CXR (PA & lateral; see Radiology inserts) → tap effusions if >5 cm or severe PNA
* Other: S a O 2 or P a O 2 , arterial pH (if severe), CBC w/ diff, Chem-20; HIV test (if unknown)
* Other micro based on clinical suspicion (paired serologies available for most atypicals):
  * Mycoplasma: PCR of throat or sputum/BAL before first dose abx 
  * Legionella urinary Ag (detects L. pneumophila L1 serotype, 60–70% of clinical disease) 
  * S. pneumoniae urinary Ag (Se 70%, Sp >90%) 
  * MTb: (induced) sputum AFB stain ×3 q ≥8h (w/ ≥1 early morning specimen). Myco-bacterial cx (empiric respiratory isolation while pending); MTb DNA PCR if smear ⊕
* Viral testing (DFA or PCR) on nasopharyngeal swab or sputum
* Bronchoscopy: consider if immunosupp., critically ill, failing to respond, VAP, suspected TB or PCP, or inadequate or Θ sputum cx. Some pathogens need specific cx media (eg, Legionella on BCYE).
* Reasons for failure to improve on initial Rx:
  * Insufficient time: may take ≥72 h to see improvement (fever persists >4 d in ~20%) 
  * Insufficient drug levels for lung penetration (eg, vanco trough <15–20 µg/mL) 
  * Resistant organisms (or superinfxn): eg, MRSA, Pseudo.; consider bronchoscopy 
  * Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; consider CT 
  * Parapneumonic effusion/empyema/abscess: if CXR Θ, consider CT (dx tap ± chest tube if effusion present, esp. if loculated) 
  * Metastatic infection (eg, endocarditis, meningitis, septic arthritis)

## Triage

* qSOFA predicts poor outcomes, prolonged ICU stay, and inhospital mortality if >2 of 3: RR>22, AMS, SBP<100 (JAMA 2016; 315:801)
* CURB-65: confusion, BUN >20, RR >30, BP <90/60, age >65 If score 0–1: Rx as outpt; 2: Rx as inpt; >3 consider ICU (Thorax 2013; 58:377)
* ![PulmCrit- Top ten problems with the new sepsis definition](https://i.imgur.com/lVd0Yur.gif)

![figure 2.5.1](https://i.imgur.com/XJkLR6q.png)

## Treatment

![table 2.7.1](https://i.imgur.com/b0aaXc1.jpg)

| Scenario         | Regimen                                                      | Special Considerations                                       |
| ---------------- | ------------------------------------------------------------ | ------------------------------------------------------------ |
| CAP (outPt)      | Azithro or doxy                                              | Avoid azithro/doxycycline if >25% resist- ance locally. Use FQ OR B-lactam + azithro/doxy. |
| CAP (ward)       | Resp FQ or [3 rd -gen ceph + azithro]                        | Doxycycline can replace azithro Omadacycline ≈ FQ (NEJM  2019;380:517) |
| CAP (ICU)        | Resp FQ + [3 rd -gen ceph or amp-sulbactam]                  | Only cover MRSA or Pseudomonas if risk factors. If resp FQ contraindic., use azithro |
| HCAP (incl. VAP) | [Pip-tazo or cefepime or carbapen.] + [vanco or linezolid]395 | May add resp FQ (or azithro) when concerned re: atypicals    |
| Aspiration       | Treat if abnl CXR (or if need to be intubated or develops septic shock) Amox-clav, amp-sulbactam, FQ, carbapenem | If hosp-acquired and concern for multidrug-resistant  pathogens: [pip-tazo, cefepime, or carbapenem] + [AG or colistin] |

* Avoid quinolones if suspect TB
* Steroids: not standard practice, but appear to ↓ mortality, mech vent, & ARDS (Cochrane 2017;12:CD007720). Consider in severe CAP (F i O 2 >0.5 + ≥1 of: pH<7.3; lactate >4; CRP >150). Avoid in suspected or known influenza. Dosing: pred 50 mg PO ×7 d or methylpred 0.5 mg/kg IV BID ×5 d.
* Duration: for CAP, 5 d if stable & afebrile for 48–72 h; for HAP/VAP, 8 d (CID 2017; 65:8)
* When possible, de-escalate abx based on sensitivities
* ![figure 2.5.2](https://i.imgur.com/503CDow.png)

## Prognosis

* For low-risk Pts, can discharge immediately after switching to PO abx (CID 2007;44:S27)
*  CXR resolves in most by 6 wk; consider f/u to r/o underlying malig (esp. if >50 y or smoker)

## Prevention

* All persons >65: give PCV13 vaccine followed by PPSV23 vaccine 1 y later. If PPSV23 already received, give PCV13.
* Age 19–64 w/ CHF/CMP, lung disease (including asthma), cirrhosis, DM, EtOH, or smoker: give PPSV23
* Any age w/ immunocomp., CSF leak, cochlear implant, asplenia: give PCV13 followed by PPSV23 8 wks later.
* Smoking cessation counseling
* VAP precautions: HOB >30°, chlorhexidine rinse; aspiration precautions in high-risk Pts